Kjellin M., Wesslén T., Löfblad E., Lennerstrand J., and Lannergård A. “The Effect of the First-Generation HCV-Protease Inhibitors Boceprevir and Telaprevir and the Relation to Baseline NS3 Resistance Mutations in Genotype 1: Experience from a Small Swedish Cohort”. Upsala Journal of Medical Sciences, vol. 123, no. 1, Mar. 2018, pp. 50–56, doi:10.1080/03009734.2018.1441928.